Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineDaniel D. Von Hoff, Markus F. Renschler, Nathan Bahary et al.|New England Journal of Medicine|2013Cited by 6.6k
Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE StudyHoward S. Höchster, Eric Hedrick, Lowell L. Hart et al.|Journal of Clinical Oncology|2008Cited by 623
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract CancersRachna T. Shroff, Mitesh J. Borad, Milind Javle et al.|JAMA Oncology|2019Cited by 472
Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107Axel Grothey, Daniel J. Sargent, Eric Hedrick et al.|Journal of Clinical Oncology|2008Cited by 171
Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-StudyH. S. Hochster, Barrett H. Childs, Lowell L. Hart et al.|Journal of Clinical Oncology|2006Cited by 137